Not only continuous glucose monitoring systems (CGM) and continuous subcutaneous insulin infusion (CSII or insulin pumps), but also innovative systems connecting both devices with algorithms to facilitate automated insulin delivery (AID, or “hybrid closed loop”, HCL) have been increasingly used by people with T1D in high-income countries over the past decade (1–3). Here, INS is linked to type 1 diabetes mellitus.